Abstract
In this study we describe a method to identify important genes that appear to be involved in the cytotoxic mechanisms of key molecular fragments (biophores) contained within the structures of anticancer compounds. The anticancer biophores were mined by the MULTICASE program by analyzing 60 datasets containing 3271 compounds tested against the NCI-60 human cancer cell lines. For each identified fragment, statistically relevant genes were found by relating the activity profiles of the molecules containing the fragment and the gene expression profiles of the different cell lines. Microarray gene expression data of 13111 genes was used in conjunction with the LeFE algorithm to accomplish this task. We have demonstrated that regression analysis can then predict the cytotoxic activity of a compound in cell lines outside of those included in the regression model, even if it belongs to a different cancer type provided that the expression levels of identified genes are known for the cell lines. It is hoped that identifying key genes within the context of specific substructures responsible for the cytotoxic activity of anticancer agents could offer a better handle for designing specialized drugs targeting specific tumors based on their genetic profile.
Keywords: NCI-60, MULTICASE, anti-cancer, chemogenomics, cancer genes
Current Computer-Aided Drug Design
Title: Finding Relevant Genes Involved in the Cytotoxicity Mechanisms of Anticancer Biophores
Volume: 5 Issue: 4
Author(s): Suman K. Chakravarti and Gilles Klopman
Affiliation:
Keywords: NCI-60, MULTICASE, anti-cancer, chemogenomics, cancer genes
Abstract: In this study we describe a method to identify important genes that appear to be involved in the cytotoxic mechanisms of key molecular fragments (biophores) contained within the structures of anticancer compounds. The anticancer biophores were mined by the MULTICASE program by analyzing 60 datasets containing 3271 compounds tested against the NCI-60 human cancer cell lines. For each identified fragment, statistically relevant genes were found by relating the activity profiles of the molecules containing the fragment and the gene expression profiles of the different cell lines. Microarray gene expression data of 13111 genes was used in conjunction with the LeFE algorithm to accomplish this task. We have demonstrated that regression analysis can then predict the cytotoxic activity of a compound in cell lines outside of those included in the regression model, even if it belongs to a different cancer type provided that the expression levels of identified genes are known for the cell lines. It is hoped that identifying key genes within the context of specific substructures responsible for the cytotoxic activity of anticancer agents could offer a better handle for designing specialized drugs targeting specific tumors based on their genetic profile.
Export Options
About this article
Cite this article as:
Chakravarti K. Suman and Klopman Gilles, Finding Relevant Genes Involved in the Cytotoxicity Mechanisms of Anticancer Biophores, Current Computer-Aided Drug Design 2009; 5 (4) . https://dx.doi.org/10.2174/157340909789577883
DOI https://dx.doi.org/10.2174/157340909789577883 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation
Current Pharmaceutical Biotechnology In Vivo Roles of CDC25 Phosphatases: Biological Insight into the Anti-Cancer Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design Efficient Loading and Controlled Release of Benzophenone-3 Entrapped into Self-Assembling Nanogels
Current Nanoscience Acridone-based Antitumor Agents: A Mini-review
Anti-Cancer Agents in Medicinal Chemistry Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer Activities
Anti-Cancer Agents in Medicinal Chemistry Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Current Pharmaceutical Design Epidemiology of Vitamin D and Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Genotoxicity of Nanocarriers
Current Drug Metabolism Biomarkers of Regenerative Responses to Phenytoin in Periosteal Fibroblasts and Modulation by Histamine; Relevance to Inflammatory Repair
Recent Patents on Biomarkers Fish and Apoptosis: Molecules and Pathways
Current Pharmaceutical Design Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Recent Progress in Radiofluorination of Peptides for PET Molecular Imaging
Current Organic Synthesis Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry